Endologix LLC (Endologix) is a medical equipment company that develops, manufactures and markets minimally invasive devices in treatment of aortic diseases. The company incorporates its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA) and ALTO Abdominal Stent Graft System. The company’s AAA products are built on traditional minimally invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform and Ovation system. The company’s EVAR products include AFX endovascular AAA system, the VELA proximal endograft, the ovation abdominal stent graft system. Its ALTO products are developed with adaptive sealing technology, low profile delivery system, and shortest neck indication system specialized for anatomies, including tortuous iliacs and short necks. It has manufacturing facility in Irvine and Santa Rosa, California. The company sells products in the US and six other countries through direct sales force. It also sells products through third-party distributors and agents in Asia Pacific, Latin America, Europe, and other targeted international geographies. Endologix is headquartered in Irvine, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Endologix LLC
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Endologix LLC Company Overview
Endologix LLC Company Snapshot
Endologix LLC Pipeline Products and Ongoing Clinical Trials Overview
Endologix LLC – Pipeline Analysis Overview
Business Description
Endologix LLC - Key Facts
Endologix LLC - Major Products and Services
Endologix LLC Pipeline Products by Development Stage
Endologix LLC Ongoing Clinical Trials by Trial Status
Endologix LLC Pipeline Products Overview
AFX2 Bifurcated Endograft System
AFX2 Bifurcated Endograft System Product Overview
AFX3
AFX3 Product Overview
AFX4
AFX4 Product Overview
Nellix 3.5
Nellix 3.5 Product Overview
Nellix CHEVAS
Nellix CHEVAS Product Overview
Nellix CHEVAS Clinical Trial
Nellix EVAS System
Nellix EVAS System Product Overview
Nellix EVAS System Clinical Trial
Nellix With Snorkels
Nellix With Snorkels Product Overview
Next Gen EVAS
Next Gen EVAS Product Overview
Ovation Thoracic Stent Graft System
Ovation Thoracic Stent Graft System Product Overview
Paravisceral System
Paravisceral System Product Overview
PQ Crossing Device
PQ Crossing Device Product Overview
PQ Snare
PQ Snare Product Overview
TORUS Stent Graft System
TORUS Stent Graft System Product Overview
TORUS Stent Graft System Clinical Trial
Ventana 2
Ventana 2 Product Overview
Xpand BX Covered Stent
Xpand BX Covered Stent Product Overview
Endologix LLC - Key Competitors
Endologix LLC - Key Employees
Endologix LLC - Key Employee Biographies
Endologix LLC - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Endologix LLC, Recent Developments
Jul 05, 2020: Endologix enters into an agreement with Deerfield Partners to take the company private
May 11, 2020: Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020
Feb 19, 2020: Endologix reports fourth quarter and fiscal year 2019 financial results
Jan 10, 2020: PQ Bypass announces 100th patient in clinical study to evaluate percutaneous fem-pop bypass for extremely long blockages in leg arteries
Dec 19, 2019: CMS approves coverage for PQ Bypass TORUS 2 IDE trial
Nov 06, 2019: Endologix reports third quarter 2019 financial results
Nov 04, 2019: PQ Bypass initiates pivotal study of next-generation advancement in Stent Graft Technology for Treatment of Patients with Peripheral Artery Disease
Oct 29, 2019: Endologix comments on recent FDA update on Type III Endoleaks with AFX Endovascular AAA System
Oct 28, 2019: Update on risk of type III endoleaks with use of Endologix AFX Endovascular AAA Graft Systems: FDA safety communication
Oct 08, 2019: PQ Bypass announces unconditional IDE approval from U.S. FDA to start TORUS SFA Stent Graft Pivotal Study (TORUS-2)
Table 10: AFX2 Bifurcated Endograft System - Product Status
Table 11: AFX2 Bifurcated Endograft System - Product Description
Table 12: AFX3 - Product Status
Table 13: AFX3 - Product Description
Table 14: AFX4 - Product Status
Table 15: AFX4 - Product Description
Table 16: Nellix 3.5 - Product Status
Table 17: Nellix 3.5 - Product Description
Table 18: Nellix CHEVAS - Product Status
Table 19: Nellix CHEVAS - Product Description
Table 20: Nellix CHEVAS - Prospective, Multicenter, Non-randomized Study with Consecutive, Eligible Subject Enrollment at Each Site, for the Evaluation of the ChEVAS System for Endovascular Repair of Paravisceral, Juxtarenal, and Pararenal Abdominal Aortic Aneurysms
Table 21: Nellix EVAS System - Product Status
Table 22: Nellix EVAS System - Product Description
Table 23: Nellix EVAS System - Multicenter, Observational, Registry to Assess Outcomes of Patients Treated With the CE Marked Nellix System for Endovascular Abdominal Aortic Aneurysm Repair
Table 24: Nellix EVAS System - Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix System IDE Study: EVAS 2 Confirmatory IDE Study
Table 25: Nellix With Snorkels - Product Status
Table 26: Nellix With Snorkels - Product Description
Table 27: Next Gen EVAS - Product Status
Table 28: Next Gen EVAS - Product Description
Table 29: Ovation Thoracic Stent Graft System - Product Status
Table 30: Ovation Thoracic Stent Graft System - Product Description
Table 31: Paravisceral System - Product Status
Table 32: Paravisceral System - Product Description
Table 37: TORUS Stent Graft System - Product Status
Table 38: TORUS Stent Graft System - Product Description
Table 39: TORUS Stent Graft System - Long Segment Lesion Peripheral Artery Revascularization Feasibility Study
Table 40: TORUS Stent Graft System - The PQ Bypass Pivotal IDE Intra-arterial Stent Graft Study for Occlusive and Re-stenotic Fem-pop Revascularization - 2 Trial: TORUS 2